Noah Graham

715 total citations · 1 hit paper
26 papers, 290 citations indexed

About

Noah Graham is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Noah Graham has authored 26 papers receiving a total of 290 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 9 papers in Cancer Research and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Noah Graham's work include Breast Cancer Treatment Studies (6 papers), Advanced Breast Cancer Therapies (4 papers) and HER2/EGFR in Cancer Research (4 papers). Noah Graham is often cited by papers focused on Breast Cancer Treatment Studies (6 papers), Advanced Breast Cancer Therapies (4 papers) and HER2/EGFR in Cancer Research (4 papers). Noah Graham collaborates with scholars based in United States, Australia and Spain. Noah Graham's co-authors include Peter J. O’Dwyer, Paul J. Catalano, Brock A. Martin, James C. Yao, Andrew Hendifar, Manisha H. Shah, George A. Fisher, Mark M. Zalupski, Pamela L. Kunz and Matthew H. Kulke and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Noah Graham

25 papers receiving 288 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)

2022 125 citations Pamela L. Kunz, Noah Graham et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Noah Graham

Since Specialization

Citations

This map shows the geographic impact of Noah Graham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Noah Graham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Noah Graham more than expected).

Fields of papers citing papers by Noah Graham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Noah Graham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Noah Graham. The network helps show where Noah Graham may publish in the future.

Co-authorship network of co-authors of Noah Graham

This figure shows the co-authorship network connecting the top 25 collaborators of Noah Graham. A scholar is included among the top collaborators of Noah Graham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Noah Graham. Noah Graham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract RF5-02: Tbcrc 056: a phase 2 study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: results from the TNBC cohorts 2026 ·Clinical Cancer Research ·(unknown), Noah Graham, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Justin M. Balko, (unknown), Adrian Schubert, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
2	Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer 2025 ·Journal for ImmunoTherapy of Cancer ·Ana C. Garrido-Castro, Noah Graham, Lestat R. Ali, Christina I. Herold, (unknown), Khanh Do, Heather A. Parsons, Tianyu Li, Shom Goel, (unknown), Eileen Wrabel, Amy J. Williams, (unknown), Elizabeth A. Mittendorf, Stephanie K. Dougan, Nabihah Tayob, Geoffrey I. Shapiro, Sara M. Tolaney	5
3	Overall side‐effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments 2025 ·Cancer ·John Devin Peipert, (unknown), Fengmin Zhao, Ju‐Whei Lee, Jessica Roydhouse, Edward H. Ip, Nathaniel S. O’Connell, Ruth C. Carlos, Noah Graham, Mary Lou Smith, Ilana F. Gareen, Ahmad A. Tarhini, Tait D. Shanafelt, (unknown), (unknown), David Cella, Robert J. Gray, Lynne I. Wagner	0
4	A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174). 2024 ·Journal of Clinical Oncology ·Jennifer R. Eads, Noah Graham, Michael K. Gibson, Lakshmi Rajdev, Anuradha Chakravarthy, Onkar V. Khullar, Steven H. Lin, Ignacio I. Wistuba, Rajiv Agarwal, (unknown), (unknown), Tareq Al Baghdadi, Ning Jin, Ryan Massa, Stanley R. Hamilton, Charles A. Staley, Terence Z. Wong, Peter J. O’Dwyer	10
5	Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer 2024 ·European Journal of Cancer ·Paolo Tarantino, (unknown), Noah Graham, (unknown), (unknown), Melissa E. Hughes, Nabihah Tayob, Ana C. Garrido-Castro, Stefania Morganti, Tari A. King, Elizabeth A. Mittendorf, Giuseppe Curigliano, Nancy U. Lin, Sara M. Tolaney	12
6	Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer 2024 ·ESMO Open ·Albert Grinshpun, Shan Ren, Noah Graham, (unknown), Eileen Wrabel, John A. Carter, Nabihah Tayob, (unknown), (unknown), Dejan Juric, (unknown), SM Tolaney, Ian E. Krop, Otto Metzger	4
7	213P Sequencing antibody-drug conjugates (ADCs) in patients (pts) with HER2-negative (HER2-) metastatic breast cancer (mBC) 2024 ·ESMO Open ·(unknown), (unknown), Noah Graham, Melissa E. Hughes, (unknown), Karen L. Smith, (unknown), (unknown), Stefan Buck, (unknown), Abigail Moore, Ana C. Garrido-Castro, Alessandro Giordano, Henrique A. Parsons, A. Prat, Nabihah Tayob, Nancy U. Lin, SM Tolaney	3
8	Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma 2024 ·JAMA Network Open ·John Devin Peipert, Fengmin Zhao, Ju‐Whei Lee, (unknown), Edward H. Ip, Nathaniel S. O’Connell, Ruth C. Carlos, Noah Graham, Mary Lou Smith, Ilana F. Gareen, (unknown), Matthias Weiss, Shaji Kumar, S. Vincent Rajkumar, David Cella, Robert J. Gray, Lynne I. Wagner	10
9	Estimating mortality in women with triple-negative breast cancer: The ‘ESTIMATE triple-negative’ tool 2023 ·European Journal of Cancer ·José Pablo Leone, (unknown), Noah Graham, (unknown), (unknown), Sara M. Tolaney, Bernardo Amadeo Leone, Rachel A. Freedman, Michael J. Hassett, Carlos Vallejo, Eric P. Winer, Nancy U. Lin, Nabihah Tayob	2
10	Abstract PD6-08: PD6-08 Mortality risks over 20 years in men with stage I-III hormone receptor-positive breast cancer 2023 ·Cancer Research ·Julieta Leone, Michael J. Hassett, Rachel A. Freedman, Sara M. Tolaney, Noah Graham, Nabihah Tayob, Carlos Vallejo, Eric P. Winer, Nancy U. Lin, José Pablo Leone	2
11	Abstract CT188: A phase Ib study of sapacitabine (sapa) and olaparib (ola) in patients (pts) with BRCA1/2-mutated (BRCA1/2m) metastatic breast cancer (MBC) 2023 ·Cancer Research ·Filipa Lynce, Noah Graham, Bose Kochupurakkal, Huy Nguyen, Philip D. Poorvu, Victoria Attaya, (unknown), (unknown), Lee P. Lim, Mark Li, Cloud P. Paweletz, Nabihah Tayob, Geoffrey I. Shapiro, Sara M. Tolaney	3
12	6P Combined analysis of the HER2DX genomic tool in adjuvant APT and ATEMPT trials 2023 ·ESMO Open ·Paolo Tarantino, Guillermo Villacampa, Noah Graham, Adrienne G. Waks, (unknown), (unknown), (unknown), Patricia Galván, (unknown), (unknown), Ann H. Partridge, Harold J. Burstein, Ian E. Krop, Nabihah Tayob, Eric P. Winer, Aleix Prat, Sara M. Tolaney	1
13	Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial 2023 ·Journal of Clinical Oncology ·Nathaniel S. O’Connell, Fengmin Zhao, Ju‐Whei Lee, Edward H. Ip, John Devin Peipert, Noah Graham, Mary Lou Smith, Ilana F. Gareen, Ruth C. Carlos, Samilia Obeng‐Gyasi, Joseph A. Sparano, Tait D. Shanafelt, Mary L. Thomas, David Cella, Lynne I. Wagner, Robert J. Gray	23
14	Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer 2022 ·npj Breast Cancer ·Joseph A. Sparano, Anne O’Neill, Noah Graham, Donald W. Northfelt, Chau T. Dang, Antonio C. Wolff, George W. Sledge, Kathy D. Miller	20
15	Estimating long-term mortality in women with hormone receptor-positive breast cancer: The ‘ESTIMATE’ tool 2022 ·European Journal of Cancer ·José Pablo Leone, (unknown), Noah Graham, Sara M. Tolaney, Bernardo Amadeo Leone, Rachel A. Freedman, Michael J. Hassett, Julieta Leone, Carlos Vallejo, Eric P. Winer, Nancy U. Lin, Nabihah Tayob	4
16	Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211) breakdown → 2022 ·Journal of Clinical Oncology ·Pamela L. Kunz, Noah Graham, Paul J. Catalano, Halla Nimeiri, George A. Fisher, Teri A. Longacre, Carlos J. Suarez, Brock A. Martin, James C. Yao, Matthew H. Kulke, Andrew Hendifar, James C. Shanks, Manisha H. Shah, Mark M. Zalupski, (unknown), Diane Reidy‐Lagunes, Jonathan Strosberg, Peter J. O’Dwyer, Al B. Benson	125
17	Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients 2022 ·Blood Cancer Journal ·Samilia Obeng‐Gyasi, Noah Graham, Shaji Kumar, Ju‐Whei Lee, Susanna Jacobus, Matthias Weiss, David Cella, Fengmin Zhao, Edward H. Ip, Nathaniel S. O’Connell, Fangxin Hong, (unknown), Ilana F. Gareen, Lava Timsina, Robert J. Gray, Lynne I. Wagner, Ruth C. Carlos	16
18	EA2183: A phase III study of consolidative radiotherapy in patients with oligometastatic HER2-negative esophageal and gastric adenocarcinoma. 2022 ·Journal of Clinical Oncology ·Nataliya V. Uboha, Noah Graham, Lakshmi Rajdev, Michael K. Gibson, George A. Fisher, Steven H. Lin, Bapsi Chakravarthy, Peter J. O’Dwyer	2
19	Factors associated with late risks of breast cancer-specific mortality in the SEER registry 2021 ·Breast Cancer Research and Treatment ·José Pablo Leone, Carlos Vallejo, Michael J. Hassett, Julieta Leone, Noah Graham, Nabihah Tayob, Rachel A. Freedman, Sara M. Tolaney, Bernardo Amadeo Leone, Eric P. Winer, Nancy U. Lin	16
20	Correction to: Factors associated with late risks of breast cancer‑specific mortality in the SEER registry 2021 ·Breast Cancer Research and Treatment ·José Pablo Leone, Carlos Vallejo, Michael J. Hassett, Julieta Leone, Noah Graham, Nabihah Tayob, Rachel A. Freedman, Sara M. Tolaney, Bernardo Amadeo Leone, Eric P. Winer, Nancy U. Lin	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact